<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0301-696X</journal-id>
<journal-title><![CDATA[Revista de sanidad militar]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. sanid. mil.]]></abbrev-journal-title>
<issn>0301-696X</issn>
<publisher>
<publisher-name><![CDATA[Secretaría de la Defensa Nacional, Dirección General de Sanidad]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0301-696X2018000200118</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Supervivencia de pacientes con adenocarcinoma pulmonar y mutación en el receptor del factor de crecimiento epidérmico]]></article-title>
<article-title xml:lang="en"><![CDATA[Survival of patients with pulmonary adenocarcinoma and mutation in the epidermal growth factor receptor]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez Torres]]></surname>
<given-names><![CDATA[Wendy Rosangela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Zincer]]></surname>
<given-names><![CDATA[Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres Alarcón]]></surname>
<given-names><![CDATA[Carmen Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Central Militar  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Central Militar  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Central Militar  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2018</year>
</pub-date>
<volume>72</volume>
<numero>2</numero>
<fpage>118</fpage>
<lpage>124</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0301-696X2018000200118&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0301-696X2018000200118&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0301-696X2018000200118&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción  El carcinoma pulmonar es la causa mayor de muertes por cáncer en el mundo; la expresión del receptor del factor de crecimiento epidérmico (EGFR) en tejido de carcinoma pulmonar se presenta en la estirpe adenocarcinoma. La utilización de inhibidores de tirosina cinasa que actúan sobre dicho receptor ha incrementado la supervivencia mayor de dos años en pacientes EGFR mutados.  Objetivo Conocer el efecto de los inhibidores tirosina cinasa en la supervivencia de pacientes con adenocarcinoma pulmonar y receptor del factor de crecimiento epidérmico mutado.  Material y métodos  Se realizó un estudio observacional, analítico, retrospectivo y transversal en un periodo de dos años (2013 al 2015); fueron incluidos pacientes con diagnóstico confirmado de cáncer pulmonar y la presencia de EGFR mutado realizado por FISH (siglas del inglés fluorescent in situ hybridization). La supervivencia se evaluó mediante prueba de Kaplan-Meier, Logrank o regresión de Cox, considerando una significancia estadística asociada a un valor de p &#8804; 0.005.  Resultados  Fueron incluidos 13 pacientes; su edad promedio fue de 66.77 ± 9.356 años, con una mediana de 67 años; 46.2% fueron mujeres y 53.8% hombres. El tipo de deleción más común fue del exón 19 (en un 61.5%); la segunda fue de L858R (en 38.5%). Tres (23%) pacientes eran fumadores y 10 (77%) reportaron no serlo; ocho (61%) presentaron la deleción del exón 19 y cinco (39%) la deleción de L858R. Al final del estudio, seis pacientes habían sobrevivido (46%) y siete murieron (54%). El método de Kaplan-Meier arrojó 21.95 meses (IC 95% 17.3-26.61) de supervivencia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction  Pulmonary carcinoma is the leading cause of cancer deaths in the world; the expression of the epidermal growth factor receptor in lung carcinoma tissue occurs in the adenocarcinoma lineage. The use of tyrosine kinase inhibitors that act on said receptor has increased survival beyond two years in mutated EGFR patients.  Objective To know the effect of tyrosine kinase inhibitors in the survival of patients with pulmonary adenocarcinoma, mutated EGFR.  Material and methods  An observational, analytical, retrospective, transversal study was conducted over a period of two years (2013 to 2015), including patients with a confirmed diagnosis of lung cancer and the presence of the mutated EGFR performed by FISH (fluorescent in situ hybridization). The survival was evaluated by Kaplan-Meier test/Cox regression, considering a statistical significance associated with a p &#8804; 0.005.  Results Thirteen patients were included; their average age was 66.77 ± 9.356 years, with a median of 67 years; 46.2% were women and 53.8% men. The most common type of deletion was of exon 19 (in 61.5%); the second was of L858R (in 38.5%). Three (23%) patients were smokers and 10 (77%) reported not to be; eight (61%) presented deletion of exon 19 and five (39%) deletion of L858R. By the end of the study, six patients had survived (46%) and seven died (54%). The Kaplan-Meier method showed 21.95 months of survival (95% CI 17.3-26.61).]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Adenocarcinoma pulmonar]]></kwd>
<kwd lng="es"><![CDATA[expresión del receptor del factor de crecimiento epidérmico]]></kwd>
<kwd lng="en"><![CDATA[Pulmonary adenocarcinoma]]></kwd>
<kwd lng="en"><![CDATA[expression of the epidermal growth factor receptor]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferlay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shin]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Forman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mathers]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Parkin]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2012]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2010</year>
<volume>127</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2893-917</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[León]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<source><![CDATA[Perfil epidemiológico de los tumores malignos en México]]></source>
<year>2013</year>
<publisher-name><![CDATA[Dirección General de Epidemiología, Secretaría de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cáncer]]></article-title>
<source><![CDATA[Organización Mundial de la Salud]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schiller]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Harrington]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Belani]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Langer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sandler]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Krook]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2002</year>
<volume>346</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>92-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gazdar]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors]]></article-title>
<source><![CDATA[Oncogene]]></source>
<year>2009</year>
<volume>28</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S24-31</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ambrogio]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Shimamura]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kubo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chirieac]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models]]></article-title>
<source><![CDATA[Oncogene]]></source>
<year>2008</year>
<volume>27</volume>
<numero>34</numero>
<issue>34</issue>
<page-range>4702-11</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sato]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shames]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Gazdar]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Minna]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A translational view of the molecular pathogenesis of lung cancer]]></article-title>
<source><![CDATA[J Thorac Oncol]]></source>
<year>2007</year>
<volume>2</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>327-43</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Settleman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Haber]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidermal growth factor receptor mutations in lung cancer]]></article-title>
<source><![CDATA[Nat Rev Cancer]]></source>
<year>2007</year>
<volume>7</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>169-81</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Moran]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Queralt]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Porta]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cardenal]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Camps]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Screening for epidermal growth factor receptor mutations in lung cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2009</year>
<volume>361</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>958-67</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bean]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Shih]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Riely]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Viale]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib]]></article-title>
<source><![CDATA[Proc Natl Acad Sci USA]]></source>
<year>2007</year>
<volume>104</volume>
<numero>52</numero>
<issue>52</issue>
<page-range>20932-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mok]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[YL]]></given-names>
</name>
<name>
<surname><![CDATA[Thongprasert]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Saijo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2009</year>
<volume>361</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>947-57</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitsudomi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Morita]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yatabe]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Negoro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Okamoto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Tsurutani]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2010</year>
<volume>11</volume>
<page-range>121-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maemondo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Inoue]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kobayashi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sugawara]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Oizumi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Isobe]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2010</year>
<volume>362</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>2380-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oken]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Creech]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Tormey]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Horton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[McFadden]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toxicity and response criteria of the Eastern Cooperative Oncology Group]]></article-title>
<source><![CDATA[Am J Clin Oncol]]></source>
<year>1982</year>
<volume>5</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>649-55</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eisenhauer]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Therasse]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bogaerts]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Sargent]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2009</year>
<volume>45</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>228-47</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solca]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Dahl]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zoephel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker]]></article-title>
<source><![CDATA[J Pharmacol Exp Ther]]></source>
<year>2012</year>
<volume>343</volume>
<page-range>342-50</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized phase III study of gefitinib (IRESSA&#8482;) versus standard chemotherapy (gemcitabine plus cisplatin) as a first line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung]]></article-title>
<source><![CDATA[J Thorac Oncol]]></source>
<year>2009</year>
<volume>4</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S283-4</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Shih]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Hsia]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Tsai]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Ou]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2012</year>
<volume>13</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>539-48</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thatcher]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Parikh]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ciuleanu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[von Pawel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2005</year>
<volume>366</volume>
<numero>9496</numero>
<issue>9496</issue>
<page-range>1527-37</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fukuoka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[YL]]></given-names>
</name>
<name>
<surname><![CDATA[Thongprasert]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sunpaweravong]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Leong]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Sriuranpong]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2011</year>
<volume>29</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2866-74</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lynch]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Sordella]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gurubhagavatula]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Okimoto]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Brannigan]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2004</year>
<volume>350</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2129-39</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[YL]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Feng]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[XQ]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2011</year>
<volume>12</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>735-42</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Carcereny]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gervais]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Vergnenegre]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Massuti]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Felip]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2012</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>239-46</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Hirsh]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Schuler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yamamoto]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Byrne]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mok]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2013</year>
<volume>31</volume>
<numero>27</numero>
<issue>27</issue>
<page-range>3342-50</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Azzoli]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Temin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aliff]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Baker Jr]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Brahmer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2011</year>
<volume>29</volume>
<numero>28</numero>
<issue>28</issue>
<page-range>3825-31</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Adjei]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Gridelli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Reck]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kerr]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Felip]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2012</year>
<volume>23</volume>
<numero>^s7</numero>
<issue>^s7</issue>
<supplement>7</supplement>
<page-range>vii56-64</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campos-Parra]]></surname>
</name>
<name>
<surname><![CDATA[Cruz-Rico]]></surname>
</name>
<name>
<surname><![CDATA[Arrieta]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genotipificación en cáncer de pulmón de células no pequeñas]]></article-title>
<source><![CDATA[GAMO]]></source>
<year>2012</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35-44</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
